OnabotulinumtoxinA 100 unit powder for solution for injection vial

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%